MyoKardia Drug Moves to Next Phase

Published on by hcmbeat

According to this press release, MyoKardia expects to dose the first patient in the EXPLORER-HCM trial of mavacamten (formerly known as MYK-461) for obstructive HCM in the second quarter of 2018.

MyoKardia says that it expects 220 patients to enroll in the 30 week long trial.  These patients will be randomly assigned to receive either mavacamten or a placebo.  Participants will also be able to continue on their normal beta blockers or calcium channel blockers.

 

3 thoughts on “MyoKardia Drug Moves to Next Phase”

  1. Hola buenas noches
    escribo desde chile y me gustaría saber cuando se tiene los resultados de este medicamento y cuando podrá ser utilizado en personas con esta enfermedad

    Like

    Reply
  2. Pingback: Positive Results for MyoKardia Drug Mavacamten – HCM Beat
  3. Pingback: FDA Approves Mavacamten under Brand Name Camzyos – HCM Beat

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s